HSA
CRL icon

HBK Sorce Advisory’s Charles River Laboratories CRL Stock Holding History

HBK Sorce Advisory’s Portfolio CRL Stock Details CRL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-610
Closed -$230K – 567
2021
Q4 		$230K Hold
610
– – 0.01% 524
2021
Q3 		$252K Sell
610
-37
-6% -$15.4K 0.01% 483
2021
Q2 		$239K Buy
+647
New +$216K 0.01% 503

Other funds holding CRL

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Kayne Anderson Rudnick Investment Management
Kayne Anderson Rudnick Investment Management Los Angeles, California $34B AUM 6.31% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return
William Blair Investment Management
William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

HBK Sorce Advisory's CRL Position: Q1 2022 in Review

HBK Sorce Advisory sold out of Charles River Laboratories (CRL) in Q1 2022, closing a stake of 610 shares — an estimated $230K sold.

HBK Sorce Advisory first reported a position in CRL in Q2 2021 and held it in 3 quarters. The position peaked at $252K in Q3 2021. 644 funds tracked by Wall St. Rank hold CRL as of Q1 2022.

  • HBK Sorce Advisory reported no remaining Charles River Laboratories position as of Q1 2022 after selling out during the quarter.
  • HBK Sorce Advisory sold 610 Charles River Laboratories shares in Q1 2022, an estimated $230K.
  • HBK Sorce Advisory first reported a position in Charles River Laboratories in Q2 2021 and held it in 3 quarters.
  • HBK Sorce Advisory's Charles River Laboratories position peaked at $252K in Q3 2021.
  • 644 funds tracked by Wall St. Rank held Charles River Laboratories as of Q1 2022.

Based on HBK Sorce Advisory's 13F filing for Q1 2022, filed 13 May 2022.